53 related articles for article (PubMed ID: 36874124)
1. Efficacy and safety of anlotinib plus anti-PD-1 agents in patients with refractory advanced biliary tract cancers.
An T; Hui Q; Zong H; Liu L; Cao X; Li R; Hu S; Liu Y; Li J; Zhao R
Clin Transl Oncol; 2024 Mar; ():. PubMed ID: 38530557
[TBL] [Abstract][Full Text] [Related]
2. Anlotinib for Metastatic Progressed Pheochromocytoma and Paraganglioma: A Retrospective Study of Real-World Data.
Tian R; Yao X; Song J; Wang J; Fu J; Shi L; Yu F; Zhang P; Zhang C; Ni Y; Wang F
J Endocr Soc; 2024 Apr; 8(6):bvae061. PubMed ID: 38650712
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of combined anlotinib-oral etoposide treatment for patients with platinum-resistant ovarian cancer.
Huang S; Sheng G; Lv Q; Li Y; Meng Q; Gao X; Shang Z
J Gynecol Oncol; 2024 Apr; ():. PubMed ID: 38670563
[TBL] [Abstract][Full Text] [Related]
4. A MRI-based radiomics model for predicting the response to anlotinb combined with temozolomide in recurrent malignant glioma patients.
Li Y; Xu W; Fei Y; Wu M; Yuan J; Qiu L; Zhang Y; Chen G; Cheng Y; Cao Y; Zhou S
Discov Oncol; 2023 Aug; 14(1):154. PubMed ID: 37612579
[TBL] [Abstract][Full Text] [Related]
5. Antiangiogenic therapy for high-grade glioma.
Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
[TBL] [Abstract][Full Text] [Related]
6. The efficacy and adverse effects of anlotinib in the treatment of high-grade glioma: A retrospective analysis.
Shen F; Li J; Liu F; Sun N; Qiu X; Ding W; Sun X
Front Oncol; 2023; 13():1095362. PubMed ID: 36874124
[TBL] [Abstract][Full Text] [Related]
7. Anlotinib as Monotherapy or Combination Therapy for Recurrent High-Grade Glioma: A Retrospective Study.
Yin J; Yin W; Zheng L; Li Y; Luo C; Zhang S; Duan L; Zhou H; Cheng K; Lang J; Xu K
Clin Med Insights Oncol; 2023; 17():11795549231175714. PubMed ID: 37435019
[TBL] [Abstract][Full Text] [Related]
8. Retrospective Study of the Safety and Efficacy of Anlotinib Combined With Dose-Dense Temozolomide in Patients With Recurrent Glioblastoma.
She L; Su L; Shen L; Liu C
Front Oncol; 2021; 11():687564. PubMed ID: 34354945
[TBL] [Abstract][Full Text] [Related]
9. Radiotherapy plus temozolomide with or without anlotinib in H3K27M-mutant diffuse midline glioma: A retrospective cohort study.
Liu C; Kuang S; Huang T; Wu J; Zhang L; Gong X
CNS Neurosci Ther; 2024 Apr; 30(4):e14730. PubMed ID: 38644565
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Anlotinib in Patients with Advanced Non-Small Cell Lung Cancer: A Real-World Study.
Zhong Q; Liu Z
Cancer Manag Res; 2021; 13():4115-4128. PubMed ID: 34045898
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of anlotinib combined with carboplatin and pemetrexed as first-line induction therapy followed by anlotinib plus pemetrexed as maintenance therapy in
He Z; Yang X; Ma T; Yang Q; Zhang C; Chen Y; Wang P; D'Incecco A; Metro G; Uematsu S; Wang Q
Transl Lung Cancer Res; 2022 Aug; 11(8):1657-1666. PubMed ID: 36090635
[TBL] [Abstract][Full Text] [Related]
12. DNA methylation-regulated SNX20 overexpression correlates with poor prognosis, immune cell infiltration, and low-grade glioma progression.
Chen X; Jiang X; Wang H; Wang C; Wang C; Pan C; Zhou F; Tian J; Niu X; Nie Z; Chen W; Huang X; Pu J; Li C
Aging (Albany NY); 2022 Jun; 14(12):5211-5222. PubMed ID: 35771139
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
